Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
4,425 USD | +2,91% | -1,88% | -50,06% |
23/04 | PRIME MEDICINE, INC. : Chardan Research herhaalt koopadvies voor het aandeel | ZM |
23/04 | PRIME MEDICINE, INC. : Chardan Research herhaalt koopadvies | ZM |
Omzet 2024 * | 14,43 mln. 13,49 mln. | Omzet 2025 * | 14,72 mln. 13,76 mln. | Marktkapitalisatie | 510 mln. 477 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -217 mln. -203 mln. | Nettowinst (verlies) 2025 * | -222 mln. -208 mln. | EV/omzet 2024 * | 27,8 x |
Nettoliquiditeiten 2024 * | 109 mln. 102 mln. | Nettoliquiditeiten 2025 * | 275 mln. 257 mln. | EV/omzet 2025 * | 16 x |
K/w-verhouding 2024 * |
-2,4
x | K/w-verhouding 2025 * |
-2,76
x | Werknemers | 234 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 74,98% |
Recentste transcriptie over Prime Medicine, Inc.
1 dag | +2,91% | ||
1 week | -1,88% | ||
Lopende maand | -36,79% | ||
1 maand | -33,56% | ||
3 maanden | -32,24% | ||
6 maanden | -26,07% | ||
Lopend jaar | -50,06% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 70 | 01-07-20 | |
Allan Reine
DFI | Director of Finance/CFO | 49 | 17/01 |
Chief Operating Officer | 52 | 01-09-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 64 | 01-12-21 | |
Robert Nelsen
BRD | Director/Board Member | 60 | 01-09-20 |
Michael Kelly
BRD | Director/Board Member | 67 | 01-11-21 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
4.71% | 2 M€ | -25,75% | ||
0.00% | 9 M€ | +6,26% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 4,425 | +2,91% | 632 912 |
25-04-24 | 4,3 | -8,51% | 848 913 |
24-04-24 | 4,7 | -2,08% | 522 474 |
23-04-24 | 4,8 | +0,42% | 850 794 |
22-04-24 | 4,78 | +5,99% | 1 445 815 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-50,06% | 496 mln. | |
-2,31% | 103 mld. | |
+0,56% | 95,71 mld. | |
+1,69% | 22,02 mld. | |
-17,37% | 20,9 mld. | |
-9,30% | 17,85 mld. | |
-41,01% | 16,21 mld. | |
-14,85% | 15,52 mld. | |
+3,21% | 13,86 mld. | |
+33,54% | 12,04 mld. |